Orphanetics Pharma Entwicklungs GmbH
1 clinical trials · Sponsor
◉ Watch Orphanetics Pharma Entwicklungs GmbH
| Record | Firm | Date |
|---|---|---|
| Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety (NCT00432822) | Orphanetics Pharma Entwicklungs GmbH |
Track Orphanetics Pharma Entwicklungs GmbH automatically
Every clearance here is in the API, with alerts when new ones post.